Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study

Histone deacetylase inhibitors are members of a class of epigenetic drugs that have proven activity in T-cell malignancies, but little is known about their efficacy in B-cell lymphomas. Abexinostat is an orally available hydroxamate-containing histone deacetylase inhibitor that differs from approved...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Haematologica
Main Authors: Ribrag, Vincent, Kim, Won Seog, Bouabdallah, Reda, Lim, Soon Thye, Coiffier, Bertrand, Illes, Arpad, Lemieux, Bernard, Dyer, Martin J. S., Offner, Fritz, Felloussi, Zakia, Kloos, Ioana, Luan, Ying, Vezan, Remus, Graef, Thorsten, Morschhauser, Franck
Formato: Artigo
Idioma:Inglês
Publicado: Ferrata Storti Foundation 2017
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5477609/
https://ncbi.nlm.nih.gov/pubmed/28126962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.154377
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares